Public Day Care Centers
Badi Bassit, São Paulo, Brazil
NCT Number: NCT00992823
Aim: To evaluate the efficacy of iron supplements given at intervals corresponding to the mean life of red blood cells compared to weekly supplementation, in reducing the prevalence of preschool anemia.
Method: Ninety-nine children from public day care centers with ages from 24 to 59 months old were randomly divided into two groups. All the children received 40 doses of 30 mg of ferrous sulfate during a 10-month intervention period. Group 1 received once weekly supplementation and Group 2 received supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
Looking for future studies?
Notify Me24 month–59 month
All sexes
Interventional
Not applicable
Badi Bassit, São Paulo, Brazil
The prevalence of anemia after the supplementation regimens reduced from 20.20% to 5.05% (P < 0.0005); the reduction was not significantly different between the two groups (P = 0.35). The mean hemoglobin concentration increased in both groups (Group 1: 0.27 g/dL; P < 0.016 and Group 2: 0.47 g/dL; P < 0.0005) without significant differences between the groups (P = 0.17).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
Time frame: 10 months
Looking for future studies?
Notify MeSao Jose do Rio Preto Medical School
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03459287
Anemia, Hematologic Diseases
Los Angeles, California, United States
View Trial DetailsNCT03558464
Anemia, Growth Disorders
Kakamega, Kenya
View Trial DetailsNCT05889052
Anemia, Hematologic Diseases
Soa and Mbankomo, Cameroon
View Trial DetailsNCT05856357
Anemia, Hematologic Diseases
Séguéla, Côte d’Ivoire
View Trial Details